CHRW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
C.H. Robinson Worldwide Inc (CHRW) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company has some positive catalysts such as its technological advancements and structural advantages post-Montgomery decision, the stock's recent price action, insider selling trends, and mixed analyst sentiment suggest limited near-term upside. Additionally, Congress trading data shows cautious behavior with more selling activity. Given the investor's preference for long-term growth, it may be better to monitor the stock for a more favorable entry point or consider other opportunities.
The stock's technical indicators are mixed. The MACD is negative and expanding downward, indicating bearish momentum. RSI is neutral at 44.921, showing no clear overbought or oversold conditions. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting a longer-term uptrend. Key support is at $182.315, and resistance is at $193.5, with the current price near support levels.
Launch of BidBoardX, a digital freight tool, enhancing operational efficiency and market transparency.
Structural advantages in a post-Montgomery regulatory environment, favoring scaled brokers like CHRW.
Analysts highlight the company's technology and productivity transformation as a long-term growth driver.
Insiders are selling heavily, with a 1551.76% increase in selling activity over the last month.
Congress trading data shows more selling than buying, indicating cautious sentiment.
Citi downgraded the stock to Neutral, citing valuation concerns after a 21% price increase in the past month.
The MACD and short-term stock trend suggest potential bearish momentum in the near term.
C.H. Robinson reported $16.2 billion in revenue for FY 2025, an 8% decline year-over-year, but net income was $587 million. The company's forward P/E ratio of 31.1x is significantly higher than peers, reflecting its profitability but also raising valuation concerns.
Analyst sentiment is mixed. While UBS, Jefferies, and JPMorgan maintain Buy or Overweight ratings with price targets ranging from $196 to $230, Citi recently downgraded the stock to Neutral due to valuation concerns. The stock has seen multiple price target increases, but the recent downgrade suggests limited upside at current levels.
